Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus (AGEN) will present new three-year overall survival data for botensilimab (BOT) plus balstilimab (BAL) in recurrent ovarian cancer at the IGCS Annual Global Meeting, held October 1–3, 2026, in Montreal, Canada.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

The presentation will feature results from the recurrent ovarian cancer cohort of the large Phase 1b C-800-01 study, including patients with platinum-refractory/resistant disease, with analyses by platinum sensitivity status and long-term three-year overall survival.

Presentation Details:

Abstract Title: Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival
Presenter: Rebecca L. Porter, M.D.; Dana-Farber Cancer Institute, Boston, MA, USA
Poster Presentation number: 969
Session Title: Poster Rounds with Professors Session, Ovarian Cancer 03 Session
Date/Time: Saturday, October 3, 2026 | 10:50am-10:55am EDT

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

About Botensilimab (BOT)

Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Approximately 1,300 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260910303866/en/

Investors
917-362-1370 | investor@agenusbio.com

Media
781-674-4422 | communications@agenusbio.com

Source: Agenus Inc.

Key Terms

anti-CTLA-4 antibody medical

An anti-CTLA-4 antibody is a lab-made protein drug that binds to CTLA-4, a molecule on immune cells that acts like a brake on the body's infection- and tumor-fighting response. By blocking that brake, the antibody frees immune cells to attack cancer cells more vigorously—similar to taking off training wheels so the immune system can act more independently. Investors care because these drugs can drive large sales if proven safe and effective, but they also carry clinical trial, safety and regulatory risk that strongly affect a drug developer’s value.

anti-PD-1 antibody medical

An anti-PD-1 antibody is a lab-made protein drug that blocks a safety switch on certain immune cells, allowing them to recognize and attack cancer cells. Investors watch these drugs because trial results, approvals, or safety issues can rapidly change a biotech’s sales prospects and valuation — like cutting a car’s brake cable to free the engine, with big potential reward but also safety and regulatory risks.

platinum-refractory/resistant disease medical

Platinum-refractory/resistant disease describes cancers that stop responding to platinum‑based chemotherapy: "refractory" means the tumor either fails to shrink or gets worse during treatment or very shortly after, while "resistant" means the cancer returns or progresses within about six months after finishing a platinum regimen. This classification matters to investors because it determines which treatments or trials are relevant, shapes potential market size for new drugs, and affects regulatory and clinical development strategies.

overall survival medical

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

phase 1b medical

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.